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ABSTRACT
Asthma is a complex disorder associated with the acti-
vation of T lymphocytes and with eosinophil infiltration
within the airways. A substantial amount of current
research involves the interaction among inflammatory
cells as a result of the production of a wide array of 
T helper (h) 2 cytokines. Recent advances in the patho-
physiologic mechanisms of asthma point to the
importance of transcription factors of cytokines that
underlie the development of Th2-type responses. The
study of transcription factors has begun to reveal
mechanisms of dysregulated gene regulation in asth-
matic diathesis.
Key words: apoptosis, bronchial asthma, eosinophils,
Fas ligand, GATA-3, inflammation, STAT6, T cells,
Th2 cytokines.
INTRODUCTION
Bronchial asthma is a chronic inflammatory disease of
the airways that is characterized clinically by paroxysmal
airway constriction and increased responsiveness of the
airways to inhaled bronchoconstrictor stimuli.1 Earliest
studies from post-mortem cases of asthmatic individuals
who had died from status asthmatics2,3 revealed occlusive
mucus plugs within the bronchi, tissue eosinophilia, exten-
sive epithelial desquamation, hypertrophy/hyperplasia 
of the airway smooth muscle and a thickening of the
reticular basement membrane. The introduction of flexi-
ble fiberoptic bronchoscopy has made it possible to
elucidate the pathology of the airways of asympto-
matic or even mild asthmatic subjects. These studies on
bronchial biopsies have revealed that shedding of the
epithelial cell layer, inflammatory cell infiltration and
the deposition of collagen along the reticular basement
membrane are observed even in the most mildly affected
individuals.4–6
In addition, through the development of immunocyto-
chemical markers for inflammatory cells, it has been pos-
sible to examine their contribution to the pathophysiology
of asthma. While substantial attention has been directed
towards eosinophil and T cells, interactions between mul-
tiple cell types, including basophils, epithelial cells and
B lymphocytes, are proving to add further complexity to
asthma pathogenesis. A substantial amount of current
research involves the interaction among inflammatory
cells by cytokines. In particular, a subgroup of cytokines
that exhibit chemotactic activity for various blood cells
have been implicated in the recruitment of inflammatory
cell types to the airways. These are categorized as chemo-
kines and these chemokines coordinate the presence
of airway inflammation and, thus, may prove to be crit-
ical in the development of asthma. Furthermore, studies
into several specific transcription factors of cytokines
has begun to reveal mechanisms of disregulated gene
regulation in asthmatic diathesis, providing a new
approach for asthma therapy. This paper will focus on
recent advances in the cellular and immunologic mech-
anisms that have been identified as contributing to
asthma diathesis.
T LYMPHOCYTES
Lymphocytes amplify and coordinate adaptive immune
responses against foreign antigens. These responses are
usually self-limiting, without harmful damage to the host.
However, the presence of lymphocytes within the lungs of
asthmatic individuals appears to promote inappropriate
inflammatory cell infiltration and antibody secretion. An
increased number of lymphocytes, as determined by
morphologic criteria, is a frequent finding within the
bronchial mucosa of patients with all forms of asthma,
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from newly diagnosed to severe.2,7 These lymphocytes
appear activated, showing irregular, atypical morphol-
ogy7 and surface expression of CD25.8 These findings
suggest the fundamental role of lymphocytes in the
pathogenesis of asthma. The advent of techniques invol-
ving monoclonal antibodies (mAbs) and the detection of
mRNA have been valuable in revealing the precise
mechanisms by which these cells operate in the patho-
physiology of asthma.
To date, T lymphocytes have been broadly categorized
according to their cell surface markers, into two distinct
subsets corresponding to particular effector functions.
T cells expressing the CD4 antigen are refereed to as 
T helper (Th) cells, whereas those expressing the CD8
antigen are termed T cytotoxic/suppressor cells (TC/S).
These CD8+ cells orchestrate the cell-mediated response
and interact with endogenously processed antigen pre-
sented in conjunction with major histocompatibility com-
plex (MHC) class I. In contrast, CD4+ lymphocytes are
capable of recognizing foreign antigens processed in
association with MHC class II on the surface of profes-
sional antigen-presenting cells, such as dendritic cells.
Therefore, these CD4+ cells have attracted considerable
attention in the pathogenesis of asthma because of their
ability to drive antigen-specific inflammatory responses
and regulate immunoglobulin production. They modu-
late these functions through the secretion of specific
cytokines and chemokines.
Although T lymphocytes appear critical in the develop-
ment and maintenance of chronic allergic inflammation,
there is no consistent trend for a selective accumulation
of either CD4+ or CD8+ cells in atopic asthma. Some
studies report either no increase in either CD4+ or CD8+
cells within the airway mucosa,9 a trend towards an
increase in the number of CD4+ or CD8+ cells8 or a
selective increase in CD8+ cells.10 In non-atopic (intrinsic)
asthma, CD4+ cell numbers were reported to be elevated
within the lungs.11 Those lymphocytes within the airways
are shown to be activated, as determined by their expres-
sion of the interleukin (IL)-2 receptor (CD25).8,10 Whether
this activated state is observed for both CD4+ and CD8+
cells12 or whether it is restricted to CD3+ cells in general13
remains to be clarified. Furthermore, the activation of
these cell types has been shown to be different in atopic
and non-atopic asthma.14 These findings suggest that the
difference in the type and severity of asthma may account
for such disparity in the activation status of lymphocytes.
Activation of CD4+ cells has been shown to be present
among inflammatory infiltrates at baseline asthma, after
antigen challenge and in acute exacerbation of asthma.
The CD4+ cells in bronchoalveolar lavage fluid (BALF) of
asthmatics became more activated following antigen
challenge.15 However, allergen challenge is not associ-
ated with an increase in the numbers of CD3+ or CD4+
cells in the bronchial mucosa of asthmatics.16 In BALF, in
the early phase after allergen challenge, there may be a
loss of cells expressing the CD4 and CD8 cell marker,
suggesting that these cells are selectively retained in
the bronchial mucosa.17 Studies using ovalbumin (OVA)-
sensitized Brown Norway rats have shown that adminis-
tration of antigen (Ag)-primed CD8+ T cells suppresses
the late allergic reaction (LAR) after antigen challenge in
contrast with CD4+ cells.18 Thus, it has been suggested
that CD4+ lymphocytes promote the development of a
LAR, whereas CD8+ cells prevent this reaction. However,
a number of reports have shown the potential of CD8+
cells to promote airway inflammation in asthma. The
CD8+ cells in the bronchial mucosa and BAL-derived 
T cell clones are capable of producing cytokines impli-
cated in the pathophysiologic features of asthma, such as
IL-4, IL-5 and granulocyte–macrophage colony stimula-
ting factor (GM-CSF).19,20 Moreover, it has been sug-
gested that CD8+ T cells may precipitate a worsening 
of asthma by mediating cellular defense mechanisms
against acute viral infections, including cytotoxic action
on epithelial cells and the activation of macrophages.
Whatever their actions, CD8+ T cells comprise the minor-
ity of CD3+ lymphocytes found within the bronchial
mucosa and, thus, it is likely that they provide only a
modulatory influence over CD4+-driven inflammation.
Indeed, while both CD4 and CD8 T lymphocytes in
BALF from asthmatic subjects expressed CD25, only the
numbers of activated CD4+ cells correlated with numbers
of bronchoalveolar lavage (BAL) eosinophils and disease
severity.12
γδT CELLS
The T cell receptor consists of a disulfide-linked hetero-
dimer that, in the majority of T cells, is made up of α and
β chains. An alternative receptor consisting of γ and 
δ chains is expressed on a subset of T cells. These 
γδT cells are only rarely found within bronchial biopsy
specimens from asthmatic and normal subjects21 and
the role of T cells expressing γδ in asthma is unclear.
However, it has been shown that the proportion of 
γδT lymphocytes is higher in BALF from asthmatic patients
than controls and that these cells appeared to be allergen
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specific.22 The finding that the number of circulating 
γδ cells is reduced in asthmatic subjects23 suggests prefer-
ential recruitment from the blood stream to the lung.
Using gene-disrupted mice, γδT cells have been shown 
to be essential for initial IL-4 production, IL-4-dependent
IgE and IgG1 responses and for Th2-mediated airway
inflammation to peptide antigens.24 By releasing IL-4,
these γδT cells may actively participate in the initiation of
Th2 immune responses.
EOSINOPHILS
Elevated numbers of eosinophils in the airways is a con-
sistent feature of asthma that has been recognized for
many years for both atopic and intrinsic asthma.5,10,25–27
Post-mortem studies have revealed massive infiltration
of eosinophils around the bronchi in patients who 
died of asthma.2,28–30 Within membrane-bound gran-
ules, eosinophils store cytotoxic mediators, such as major
basic protein (MBP), eosinophilic cationic protein (MCP),
eosinophil peroxidase (MPO) and eosinophil-derived
neurotoxin (EDN). These products have consistently been
found in bronchiolar washings from both symptomatic
and asymptomatic asthmatic subjects.10,27,31,32 In animals,
MBP has been shown to provoke increased sensitivity 
to methacholine33 and inhaled antigen,34 possibly via
damage to the epithelium. Major basic protein may 
also act as an allosteric inhibitor of muscarinic M2
receptors, resulting in enhanced vagally mediated broncho-
constriction.35 Thus, once within the airways, eosino-
phils are believed to play a important role in the
pathophysiology of asthma through the release of these
mediators. Eosinophils also have the capacity to express
a large variety of cytokines and chemokines including
IL-1, -2, -3, -5, -6, -10 and -12 and transforming
growth factor (TGF)-β, tumor necrosis factor (TNF)-α,
GM-CSF, macrophage inflammatory protein (MIP)-1α
and RANTES. In terms of the host defense, these cells
are now recognized as not only contributing to the phys-
ical damage sustained by the invading pathogen, but
also to the immunoregulatory mechanisms in action.
What is interesting from a clinical viewpoint is the rela-
tionship between eosinophils within the lungs and
changes in allergen-induced lung function. The increase
in the number of eosinophils in BALF has been shown to
accompany allergen-induced early and late airway
responses.31,36–38 However, it is widely recognized that the
presence of eosinophils within the airways 24 h after
allergen challenge does not discriminate between single
and dual responders. Nevertheless, their presence within
the airways 3–4 h after challenge is associated with the
development of the LAR and the subsequent increase in
airway responsiveness.37,38 This seems to suggest that it is
not eosinophils already present in the tissue that are crit-
ical to the LAR, but rather their acute appearance within
the airways.
It is currently accepted that allergen-induced eosinophil
accumulation within lungs of asthmatics is attributed to
mature eosinophil migration from the circulation. Eosin-
ophils and basophils develop from CD34+ pluripotent
progenitor cells, which proliferate and differentiate within
the bone marrow in response to IL-3, IL-5 and GM-CSF.
For eosinophils, the terminal differentiation of committed
precursors normally occurs in the bone marrow under the
influence of IL-5. However, almost 15 years ago, a popu-
lation of eosinophil–basophil progenitors was found
within the circulation and the levels of these cells were
increased in atopic individuals.39 The number of these
eosinophil–basophil progenitors was later shown to
increase during exacerbation of asthma40 and after aller-
gen exposure.41 More recently, it has been demonstrated
that CD34+ hematopoietic cells, the earliest identified
precursor cell of eosinophils and basophils, circulate in
increased numbers in atopic subjects.42 These CD34+
cells bear the IL-5 receptor and display an increased
responsiveness to IL-5, suggesting that they are primed
towards the development of eosinophils.43
Not only are there increased numbers of circulating
eosinophil–basophil progenitors in atopic asthmatic indi-
viduals, but their production within the bone marrow can
also be upregulated in response to allergen inhalation.44
Moreover, it has been observed that there are increased
numbers of CD34+ cells as well as mature and immature
eosinophils in the bone marrow of atopic individuals,
regardless of asthmatic status.42 Interestingly, cells within
the bone marrow of dual responders differ from those 
of single responders by their increased sensitivity to 
IL-5, indicating they are already primed for eosinophil–
basophil differentiation. Indeed, there is an increase in
the proportion of CD34+ cells expressing the α subunit of
the IL-5 receptor on their surface.43
Correspondingly, several studies have shown the
involvement of these CD34+ cells in asthmatic airways.
Increased numbers of CD34+ cells within the airways
have been found in both asthmatic and non-asthmatic
individuals, denoting the presence of tissue progenitor
cells as a hallmark of atopy.45 However, the numbers of
CD34+ cells expressing αIL-5 receptor mRNA were
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increased only in asthmatic individuals, suggesting that
local differentiation takes place in the mucosa. An ex vivo
challenge study in nasal mucosal tissue has shown the
possibility of local differentiation eosinophils in situ.46
Whether or not the same mechanism plays a role in the
lungs of asthmatic subjects remains to be elucidated.
Once the concept of local differentiation is addressed,
it may then be possible to determine whether these cells
are actually proliferating in situ. It is possible that these
cells are the source of the actively dividing, presumably
hematopoietic, cells that appear in BALF within 24 h of
allergen challenge.44
DISREGULATED CELL DEATH MAY CONTRIBUTE
TO THE PERSISTENCE OF ALLERGIC
INFLAMMATION
The above discussion focused on the recruitment and
activation of inflammatory cells in the pathophysiology of
asthma. However, defects in the elimination of these
inflammatory cells are believed to facilitate the persis-
tence of chronic allergic inflammation. Indeed, there 
is increasing evidence that programmed cell death of
certain inflammatory cells is impaired in asthmatic sub-
jects. A decreased number of apoptotic eosinophils is 
a feature of asthmatic airways47,48 and peripheral blood 
T cells of asthmatic subjects fail to undergo a normal
degree of apoptosis.49
Among the molecules that are associated with apop-
tosis, Bcl-2 is well known as the anti-apoptotic molecule
and the Fas–Fas ligand system is known to promote
apoptosis. Under normal conditions, activated T cells
express the Fas antigen, which elicits activation-induced
apoptosis and limits the consequences of a persistent
immune response.
In asthmatic airways, the number of Bcl-2+ cells was
higher than in normal subjects and correlated with the
number of T lymphocytes and the severity of asthma,47
suggesting the involvement of Bcl-2 in allergic inflamma-
tion. However, it is controversial whether or not the Fas
receptor is upregulated in asthmatic inflammation. Krug
et al. have shown that, in asthmatic and control subjects,
almost all T cells in the BALF expressed Fas antigen
without changes after saline or allergen challenge and
the number of Fas ligand-expressing T cells is small
before allergen challenge.50 Interestingly, after allergen
challenge, almost all T cells found within BALF of asth-
matic patients express the Fas ligand.50 Similarly, a small
population of eosinophils in the bronchial mucosa express
Fas ligand,51 whereas eosinophils in the peripheral blood
fail to express this molecule.51,52 This suggests that the
Fas–Fas ligand system may be activated in inflammatory
cells as a consequence of local activation. Because the
increase of Fas ligand in T cells does not correspond to
the increase in the numbers of apoptotic lymphocytes,
these findings were interpreted as suggesting that this
upregulation reflects antigen-induced T cell activation
rather than cell death. On the contrary, Spinozzi et al.
have reported that T cells in BALF from asthmatic subjects
do not express surface Fas receptors nor do they contain
Fas mRNA.53 Interestingly, Th2-type cytokines, such as
IL-4, IL-5 and GM-CSF, have a dose-dependent and
specific inhibitory effect on Fas mRNA of T cells from
asthmatic subjects.54 Further study is needed to elucidate
the mechanism and role of apoptosis in the pathogenesis
of asthma.
CYTOKINE EXPRESSION IN ASTHMA
Cytokines are small, usually glycosylated proteins that
mediate communication between cells, facilitating various
functions such as chemoattraction, proliferation and dif-
ferentiation of cells and immunoglobulin isotype switch-
ing. Recently, bronchial asthma has been recognized as a
chronic inflammatory disease of the airways and cyto-
kines have been shown to play an important role in the
regulation of the inflammatory process (Fig. 1). The earli-
est reports showed the preferential expression of Th2-type
cytokines in asthmatic airways. The number of cells
expressing mRNA for IL-2, IL-3, IL-4, IL-5 and GM-CSF
increased in asthmatic airways,55,56 whereas no increase
in the number of interferon (IFN)-γ mRNA-positive cells
was observed. The specific cytokines studied to date in
asthma, with their actions and cellular sources, are sum-
marized elsewhere.57
The CD4+ Th cells have been further subdivided into
distinct phenotypes based on their profile of cytokine pro-
duction: Th1 and Th2.58 The Th2-type cells produce IL-4
and IL-5 and have been shown to differentiate from naïve
Th0 cells under the influence of IL-4. Conversely, Th1-
type cells express IFN-γ and IL-2 and are induced from
Th0-type cells by the presence of IL-12. Thus, our current
understanding is that the cytokines present at the time of
antigen exposure are one of the major determinants
directing Th cells towards either a Th1- or Th2-type
response. However, the cellular sources of IL-4 and IL-12
that induce the polarization of T cell cytokine production
remain unclear. The Th1-type cytokines are important
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regulators of cell-mediated immune responses, whereas
Th2-type cytokines mediate predominantly humoral and
eosinophilic responses. Alterations of the ratio of Th1 to
Th2 responses are important determinants of suscepti-
bility to viral and parasitic infections, allergies, antitumor
responses and autoimmunity. Observations of cytokine
expression in asthmatic airways are compatible with a
dominant Th2 response and, interestingly, both atopic
and non-atopic asthmatic subjects have a common
immunopathologic feature in terms of the increase in
Th2-type cytokines and IgE-positive cells.59,60
The Th2-type cytokines even increased after allergen
challenge within the asthmatic airways.15,16 Moreover,
treatment of asthmatic patients with steroids results in a
decrease in the numbers of IL-4 and IL-5 mRNA-posi-
tive cells and an increase in the numbers of IFN-γ
mRNA-positive cells.61 Since the original observations of
Th2-type cytokines in asthma, there has been a tremen-
dous expansion in the numbers of cytokines characterized
and there seem to be several crucial cytokines in the
pathogenesis of bronchial asthma.
Within asthmatic airways, IL-4 is presumed to be criti-
cal for the development of Th2-type cells and inhibits the
expression of the IL-12 receptor β2 subunit on T cells.62
This cytokine is also critical in the switching of B cells 
to favor IgE production.63 Interleukin-4 has also been
shown to promote goblet cell metaplasia, mucus hyper-
secretion and upregulation of vascular cell adhesion
molecule (VCAM)-1 expression in pulmonary endothelial
cells, resulting in the recruitment of eosinophils. Further-
more, IL-4 can promote the growth of eosinophils and
basophils.64 All these observations suggest the importance
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Fig. 1 Role of the cytokine and chemokine network in the pathogenesis of chronic asthma. MBP, major basic protein; ECP,
eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; MCP, eosinophilic cationic protein; MIP1-α, macrophage inflam-
matory protein-1α; IL, interleukin.
of this cytokine in eosinophilic inflammation in asthmatic
airways. In fact, inhalation of IL-4 causes the develop-
ment of sputum eosinophilia and an increased responsive-
ness of the airways.65 The major cellular sources of IL-4
mRNA within airways of both atopic and non-atopic asth-
matic subjects are CD4+ cells56,66 and, to a lesser extent,
CD8+ cells, eosinophils and mast cells.
Interleukin-5, as well as IL-3 and GM-CSF, is critical
in the production of eosinophils within the bone
marrow.67 In addition to its hematopoietic properties, 
IL-5 is a weak eosinophil chemoattractant and will
prime these cells for recruitment by other chemotactic
agents, such as eotaxin.68 Interleukin-5 mRNA expres-
sion is closely related to lung function in atopic asth-
matics.69 Remarkably, the numbers of IL-5 receptor 
α mRNA-positive cells have been shown to be associated
with the resident eosinophil infiltrate.55,61 Furthermore,
the alternative splicing of α IL-5 receptor mRNA tran-
scripts results in two isoforms (membrane bound and
soluble form) and the differential regulation of these two
isoforms may influence the eosinophil response and the
accompanying changes in lung function.70 Explanted
airways provide a useful means of examining tissue reac-
tions in the absence of inflammatory cell recruitment.
Using this technique, it has been shown that allergen
challenge results in an increase in the number of IL-5
mRNA-positive cells, suggesting that at least some of the
cytokine production is from resident inflammatory cells.71
The release of IL-5 from T cells following allergen chal-
lenge in mice has recently been postulated to induce
maturation, proliferation and, possibly, release of eosin-
ophil precursors from the bone marrow, so inducing a
systemic amplification of the immune response.72
Although activated CD4+ cells represent the major
subset of CD3+ cells within the asthmatic airways, CD8+
cells can also secrete IL-4 and IL-5.73,74 Resting peripheral
blood CD8+ cells from atopic asthmatic patients can
secrete increased levels of IL-4 compared with those from
non-atopic control subjects.75 The CD8+ cells express-
ing IL-4 and IL-5 mRNA have also been identified in
bronchial biopsies from both atopic and non-atopic asth-
matics.20 These CD8+ Th2-type cells can contribute to the
regulation of other T cells, provide B cell help and influ-
ence the production of immunoglobulins.
Interleukin-9 stimulates the proliferation of activated 
T cells, enhances the production of IgE by B cells and pro-
motes the proliferation and differentiation of both mast
cells and hematopoieteic progenitor cells. The major cellu-
lar source of this cytokine is Th2-type T cells. The locus of
the IL-9 gene has been revealed to be associated with
airway hyperresponsiveness and elevated levels of serum
IgE levels;76,77 thus, IL-9 is presumed as being a predispos-
ing factor towards the development of asthma. We have
recently demonstrated that IL-9 is increased in asthma
compared with chronic bronchitis and controls and have
shown that T cells are the major sites of production.78
Interleukin-12 stimulates the growth and activation of
T cells, natural killer cells and their production of IFN-γ.
Interleukin-12 is secreted by dendritic cells, B cells and
macrophages. The principal actions of IL-12 in atopic
disorders are to inhibit IgE synthesis and to promote the
differentiation of Th1-type cells.79 In asthmatic airways,
the expression of IL-12 mRNA is decreased, but can be
increased after treatment with steroids.80 The β2 subunit
of the IL-12 receptor is a cell surface marker of Th1-type
cells and this is remarkably reduced in the lungs of
patients with asthma.81,82
Interleukin-13 is similar to IL-4 in many ways, sharing
the IL-4 receptor α subunit for its high-affinity receptor
formation. Interleukin-13 downregulates the transcription
of IFN-γ and IL-12 and, so, may modulate the cyto-
kine environment at the time of antigen presentation.
Interleukin-13, as well as IL-4, induces IgE production
and the expression of VCAM-1 on endothelial cells and
activates eosinophils by inducing the expression of
CD69. Interleukin-13 has been shown to have a close
association with the pathophysiology of asthma. The
expression of IL-13 mRNA has been reported to increase
in atopic and non-atopic asthma80,83 and IL-13 mRNA-
positive and IL-13-immunoreactive cells are increased
24 h after segmental allergen challenge.84,85 Wills-Karp
et al.86 showed that administration of IL-13 was sufficient
to induce airway hyperresponsiveness (AHR) and admin-
istration of soluble IL-13 receptor α2 completely reversed
IL-13-mediated AHR in A/J mice. Moreover, both the
mRNA and protein for the α-specific subunit of the IL-4
receptor increased in atopic asthmatic patients com-
pared with atopic non-asthmatic individuals.87 However,
the IL-13 receptor α1, IL-13 receptor α2, IL-4 receptor α
and γ chain are proposed to form four types of IL-13
receptor complexes88 and the combination of IL-13
receptor α1 and IL-4 receptor α forms a high-affinity 
IL-13 receptor complex. The expression and role of these
receptor complexes in allergic diseases remains to be
determined.
Interleukin-16 acts through the CD4 receptor to
induce cellular migration and growth and, therefore, is 
a chemoattractant specific for CD4+ cells. This cytokine
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also induces CD25 and MHC class II expression 
on monocytes, suggesting the immunomodulatory role of
this cytokine. In asthmatic subjects, the level of IL-16 has
been shown to be increased within BALF after specific
allergen challenge,89 possibly the consequence of hista-
mine release from mast cells.90 The expression of this
cytokine is increased, even in stable asthmatics, and is
localized primarily in the epithelium.91 In non-epithelial
inflammatory cells, immunohistochemical studies have
shown that the majority of IL-16 immunoreactivity 
is colocalized with CD3+ T cells and MBP+ eosin-
ophils, with tryptase-positive mast cells making a minor
contribution.92
CHEMOKINE EXPRESSION IN ASTHMA
Chemokines are small 8–10 kDa proteins that facilitate the
movement of inflammatory cells. They are subdivided into
four families on the basis of the relative position of their
cysteine residues: CXC, CC, C, and CX3C chemokine
families. The CC chemokines, such as RANTES, eotaxin-1,
eotaxin-2, eotaxin-3 and monocyte chemoattractant pro-
tein (MCP)-2, MCP-3 and MCP-4, are the most potent
chemokines for the recruitment of eosinophils, T cells and
monocytes. Stimulated T cell chemoattractant protein-1 is
a newly identified CC chemokine with chemoattractant
activity for Th2-type cells.93 The other CC chemokines,
such as exodus-1, exodus-2, exodus-3, alternative mac-
rophage activation-associated CC chemokine-1 and
leukotactin-1, await their roles to be elucidated.
Eotaxin is the chemoattractant specific for eosinophils
that was originally found in BALF of allergen-challenged
guinea pigs.94 Several reports have shown increased
numbers of cells expressing eotaxin in biopsy samples
taken from the bronchial mucosa of patients with atopic
asthma. Both eotaxin mRNA and protein were found
within the airway epithelium and inflammatory cells,
including macrophages, eosinophils, mast cells and 
T cells. Structural cells within the airways, such as the
smooth muscle95 and fibroblast populations,96 have also
been described as potential sources of eotaxin within the
airways. This supports the concept that structural cells, as
well as inflammatory cells, participate in the immune
response through the production of chemokines and
cytokines. It is of note that the expression of eotaxin has
been shown to be associated with eosinophil infiltration
into the airways and decreased lung function after aller-
gen challenge in asthmatic subjects. Brown et al.97
demonstrated an increase in eotaxin mRNA as early as
2 h after allergen challenge in the airways of asthmatic
subjects. This increase was localized mainly to bronchial
epithelial cells, endothelial cells, macrophages, T cells,
eosinophils and mast cells. Allergen-induced release of
eotaxin correlated with the numbers of total and activated
eosinophils and the level of airflow obstruction 4 h after
allergen exposure. CCR3 is shown to be increased within
the airways of asthmatic subjects98 and cells other than
eosinophils express the eotaxin receptor CCR3, such as
basophils and Th2-type lymphocytes. However, the rel-
ative contribution of eotaxin in the recruitment of these
cells to the airways remains to be determined.
In addition to eotaxin, other chemokines, such as
RANTES, MIP-1α, MCP-3, MCP-4 and MCP-5, also
participate in the recruitment of eosinophils to sites of
inflammation. Indeed, the number of cells expressing
mRNA for eotaxin, eotaxin-2, RANTES, MCP-3, MCP-4
and CCR3 was increased significantly in both non-atopic
and atopic asthmatic subjects.98
RANTES has been shown to promote the infiltration of
eosinophils and T cells. Antigen challenge of the airways
is also associated with increase in RANTES expression
and accompanied by eosinophil and T cell infiltration.99
Furthermore, seasonal increases in eosinophil chemotac-
tic activity are induced by IL-5 and RANTES.100 Expression
of RANTES has been shown to be increased within 
the airways of atopic and non-atopic asthmatic.98,101 The
expression of this cytokine has been localized to airway
smooth muscle cells and submucosal T cells.
Monocyte chemoattractant protein-4 is another
eosinophil-associated chemokine shown to be upregu-
lated at sites of allergic inflammation. We have recently
shown the upregulation of the expression of this
chemokine in the large and small airways of asthmatic
individuals as well as eotaxin.102 The roles of other
eosinophil-associated chemokines, such as MIP-1α,
MCP-1 and MCP-3, have not yet been clarified.
TRANSCRIPTION FACTORS IN ASTHMA
During the past decade, there have been tremendous
advances in the understanding of the mechanisms of
gene regulation. This has revealed much about the
mechanisms controlling cytokine production and T cell
differentiation. Transcription factors are central to the
control of gene transcription. Once transcription factors
are activated by phospholylation, translocation to the
nucleus occurs. Then, the activated transcription factors
bind to specific recognition sites of the DNA, which are
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usually located in the upstream promoter region to facili-
tate or inhibit mRNA production. For example, IL-4
engagement with its receptor leads to phospholylation of
signal transducers and activators of transcription (STAT)-6
by Jak1 and Jak3. This causes dimerization and nuclear
translocation of STAT proteins and results in the activation
of IL-4 regulated genes, such as IL-4R, IgE, FcR and MHC
class II molecules.
In the differentiation of helper T cells, a change in
the configuration of chromatin is postulated to cause the
accessibility of specific transcription factors, leading to
the preferential production of specific cytokines. Agarwal
and Rao proposed a sequential two-step model to explain
specific cytokine gene expression in Th1 and Th2 cell
subsets.103 They showed that naïve T cells have a closed
chromatin configuration around the IL-4/IL-5/IL-13 and
IFN-γ gene loci. Once cells are induced to differentiate
by antigen and IL-4, STAT-6 is activated to yield specific
demethylation around the IL-4/IL-5/IL-13 gene locus,
resulting in a characteristic open chromatin structure
(Fig. 2). This step is accompanied by the concomitant
induction of Th2-specific transcription factors, such as
GATA-3 and c-Maf. After these Th2-specific transcription
factors bind to DNA, these tissue-specific transcription
factors synergize with more widely expressed factors, such
as activating protein (AP)-1 and NF-AT, to induce tran-
scription of Th2 genes. It appears that the open chromatin
configuration and the expression of tissue-specific tran-
scription factors are maintained in differentiated Th2
cells. Effector/memory cells are thought to be in a state
with open chromatin structure and high levels of GATA-3
and c-Maf expression. During subsequent antigenic
stimulation of the memory/effector cells, transcription
factors, such as AP-1, NF-κB, nuclear factor of acti-
vated T cells (NF-ATc) and CCAAT/enhancer-binding
proteins (C/EBPβ), are rapidly induced to synergize with
pre-existing factors, such as GATA-3 and c-Maf, causing
active transcription of the IL-4/IL-5/IL-13 gene locus in
Th2 cells.
Both AP-1 and NF-κB are particularly important in the
pathophysiology of asthma because they are responsible
for the generation of a wide range of cytokines implicated
in the asthma process, including IL-1β, TNF-α, IL-2, IL-6,
GM-CSF, MCP-1 and RANTES. In addition, steroids are
thought to exert their effect through the sequestration of
AP-1104 and steroids have also been shown to induce 
inhibitory protein-κB (I-κB), which prevents the nuclear
translocation of NF-κB and leads to the inhibition of the
production of NF-κB-dependent inflammatory cytokines.105
To date, there have been few studies examining the
expression of transcription factors in asthma. There has
been a report of an increased expression of c-fos, a com-
ponent of the transcription factor activated protein (AP-1)
in the epithelium of asthmatic airways.106 The expression
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Fig. 2 Role of transcription factors in the differentiation of T helper (Th) 2 cells. Antigen stimulation and interleukin (IL)-4 receptor
engagement activates signal transducers and activators of transcription (STAT)-6, followed by the demethylation of the IL-4/IL-5/IL-
13 locus. This demethylation causes chromatin remodelling, which allows the Th2-specific transcription factors, such as cMaf and
GATA-3, access to the IL-4/IL-5/IL-13 locus. Thereafter, more widely expressed and transiently induced transcription factors, such as
nuclear factor of activated T cells (NF-ATc), activating protein (AP)-1, nuclear factor (NF)-κB and CCAAT/enhancer-binding proteins
(C/EBP), bind to the promoter, resulting in the transcription of IL-4, IL-5 and IL-13 genes. MHC, major histocompatibility complex.
of NF-κB has been demonstrated to be upregulated in
asthmatic patients compared with non-asthmatic control
subjects.107 It has been shown that GATA-3 is pivotal to
the expression of IL-4 and IL-5108,109 and we have indi-
cated that GATA-3 mRNA is highly expressed in asthmatic
airway tissue compared with non-asthmatic control sub-
jects.110 These results also support the significant role of
GATA-3 in allergic disorders by biasing T cells in favor
of Th2-type cytokine production. Targeting this transcrip-
tion factor may provide a novel means of regulating the
local inflammatory milieu within the lungs of asthmatic
individuals.
Unlike GATA-3, c-Maf directly activates the IL-4 pro-
moter, but does not appear to regulate the expression of
all Th2 cytokine genes.111 Nuclear factor-AT has been
shown to directly activate the IL-4 promoter. Whereas
NF-Atc–/– chimeric mice displayed impaired IL-4 pro-
duction, NF-Atp–/– mice showed exaggerated and
prolonged IL-4 production and constitutive nuclear local-
ization of NF-ATc.112 Thus, unlike NF-ATc, NF-ATp can
behave as a negative regulator of Th2 responses in vivo.
Another molecule that appears to be a repressor of the
Th2 response is BCL-6. Targeted depletion of the BCL-6
gene led to eosinophilic inflammation and elevated IgE
levels.113,114 The expression of these transcription factors
and the precise role of these in the pathophysiology of
asthma remain to be understood. Targeting transcrip-
tion factors may provide a novel means of regulating
the local inflammatory milieu within the lungs of asth-
matic individuals.
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